An official website of the United States government
The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.
Here we present nonconfidential company information about a subset of awardees ready to attract third-party collaborators and investors.
4E Therapeutics , delivering innovative medicines for pain
4E Therapeutics on NIH RePorter
Aquilus Pharmaceuticals is a biotech company focused on the treatment and management of amyotrophic lateral sclerosis (ALS), neuropathic pain and other neurological disorders.
Aquilus Pharmaceuticals on NIH RePorter
Dignify Therapeutics, Restoring control of bowel and bladder dysfunction.
Dignify Therapeutics on NIH RePorter
Eysz is building an AI-based software platform that uses eye-movement data as input to identify patterns associated with consciousness, cognition, and mood to help doctors and pharma companies measure disease progression and treatment outcomes for neurological disorders starting with epilepsy.
Great Lakes NeuroTechnologies, Pioneering remote patient monitoring for Parkinson’s disease and other movement disorders.
Great Lakes Neurotechnologies on NIH RePorter
Kannalife Sciences, Inc. , a pioneering biotech company dedicated to developing small molecule therapeutics targeting inflammation.
Kannalife Therapeutics on NIH RePorter
NuvOx Therapeutics , Mobilizing Oxygen, Transforming Lives.
NuvOx Therapeutics on NIH RePorter
Palm Therapeutics is leveraging a proprietary drug discovery platform to develop first-in-class cancer therapies.
Palm Therapeutics on NIH RePorter
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS.
Pathmaker Neurosystems on NIH RePorter
Plumeria Therapeutics, Inc. is a pain therapeutic company developing a novel, non-opioid drug guided by a companion diagnostic.
Plumeria Therapeutics on NIH RePorter
Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.
Sinopia Biosciences is an AI/machine learning drug discovery company advancing novel therapeutics in neurology, oncology, and rare diseases, with a first-in-class small molecule for Parkinson’s disease.
Sinopia Biosciences on NIH RePorter
SNJ Pharma ’s SNJ101, the first plasmin-independent thrombolytic agent, aims to revolutionize the treatment of ischemic diseases by addressing the bleeding complications associated with current thrombolytic therapies, providing a therapeutic option for over 200 million patients.
South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.